Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy targets advanced prostate cancer in early trial

NCT ID NCT07140900

Recruiting now Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 29 times

Summary

This early-stage study tests a new drug called xaluritamig combined with standard hormone therapies (darolutamide or abiraterone) in 60 men whose prostate cancer has spread but still responds to hormone treatment. The main goal is to check safety and side effects, while also looking at how well the combination controls the cancer. Participants must have a specific type of prostate cancer and cannot have other cancer treatments before joining.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cabrini Hospital

    RECRUITING

    Clayton, Victoria, 3168, Australia

  • Calvary Mater Newcastle Hospital

    RECRUITING

    Waratah, New South Wales, 2298, Australia

  • Centre Hospitalier Universitaire Vaudois

    RECRUITING

    Lausanne, 1011, Switzerland

  • Chris OBrien Lifehouse

    RECRUITING

    Camperdown, New South Wales, 2050, Australia

  • Cleveland Clinic Foundation

    RECRUITING

    Cleveland, Ohio, 44195, United States

  • Dana Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • Kantonsspital Graubuenden

    RECRUITING

    Chur, 7000, Switzerland

  • Kantonsspital Sankt Gallen

    RECRUITING

    Sankt Gallen, 9007, Switzerland

  • Peter MacCallum Cancer Centre

    RECRUITING

    Melbourne, Victoria, 3000, Australia

  • Sarah Cannon Research Institute

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • The Alfred Hospital

    RECRUITING

    Melbourne, Victoria, 3004, Australia

  • Thomas Jefferson University

    RECRUITING

    Philadelphia, Pennsylvania, 19107, United States

  • University of California San Francisco

    RECRUITING

    San Francisco, California, 94158, United States

  • University of Minnesota

    RECRUITING

    Minneapolis, Minnesota, 55455, United States

Conditions

Explore the condition pages connected to this study.

METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)